Alpha Cognition (ACOG) versus Its Peers Head to Head Survey

Alpha Cognition (NASDAQ:ACOG) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Alpha Cognition to related companies based on the strength of its risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Alpha Cognition and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	1	0	3.00
Alpha Cognition Competitors	1926	5386	13952	296	2.59

Alpha Cognition presently has a consensus target price of $20.00, indicating a potential upside of 312.37%. As a group, “Biological products, except diagnostic” companies have a potential upside of 116.76%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Alpha Cognition is more favorable than its peers.

Profitability

This table compares Alpha Cognition and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-344.17%
Alpha Cognition Competitors	-2,185.76%	-161.46%	-40.62%

Institutional and Insider Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Alpha Cognition has a beta of 2.5, suggesting that its share price is 150% more volatile than the S&P 500. Comparatively, Alpha Cognition’s peers have a beta of -3.86, suggesting that their average share price is 486% less volatile than the S&P 500.

Valuation & Earnings

This table compares Alpha Cognition and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Cognition	N/A	-$13.77 million	-1.89
Alpha Cognition Competitors	$574.62 million	-$70.96 million	0.12

Alpha Cognition’s peers have higher revenue, but lower earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Alpha Cognition beats its peers on 8 of the 13 factors compared.

About Alpha Cognition

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.